Univest
Univest
  • Markets

Is Fortis Healthcare the Best Stock in Its Sector? A Look at the Numbers

  • October 13, 2026
  • Posted by: Ankit Jaiswal
  • Category: Market
No Comments
Is Fortis Healthcare the Best Stock in Its Sector? A Look at the Numbers

Fortis Healthcare CMP Rs 753 (13 Oct 2026). Market cap Rs 57,188 Cr. ROE 10.53%. P/E 53.42x versus Industry P/E 62.56x.

Quick Answer

Fortis Healthcare is one of the names investors compare when screening the Healthcare sector, built on a 10.53% return on equity and a P/E of 53.42x against an Industry P/E of 62.56x. Whether Fortis Healthcare is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Fortis Healthcare the best stock in its sector? The stock trades on the NSE at Rs 753 as of 13 October 2026, within its 52-week range of Rs 745.35 to Rs 1,104.30. Fortis Healthcare Ltd, headquartered in Gurugram, runs a network of hospitals and diagnostic centres in India, offering multi-specialty care across several cities.

Fortis Healthcare sits in the Healthcare sector, and its 10.53% ROE and 53.42x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • About Fortis Healthcare
  • Is Fortis Healthcare the Best Stock in Its Sector?
  • How Fortis Healthcare Compares Against Its Healthcare Sector Peers
  • What Makes Fortis Healthcare Worth Watching in Healthcare
  • Fortis Healthcare Valuation: Is It Justified?
  • How to Track Fortis Healthcare Before You Invest
  • Conclusion
    • Is Fortis Healthcare the best stock in its sector?
    • What is the current share price of Fortis Healthcare?
    • What sector does Fortis Healthcare belong to?
    • How does Fortis Healthcare compare to its sector peers on P/E?
    • What is Fortis Healthcare’s return on equity?
    • Should I invest in Fortis Healthcare based on its sector position?

About Fortis Healthcare

Fortis Healthcare Ltd, headquartered in Gurugram, runs a network of hospitals and diagnostic centres in India, offering multi-specialty care across several cities. Hospitals and diagnostics are its two main businesses. The stock trades about 32 percent below its 52-week high and within 1 percent of its 52-week low. At a market capitalisation of Rs 57,188 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Fortis Healthcare the Best Stock in Its Sector?

Fortis Healthcare’s case rests on valuation and a moderate balance sheet rather than on returns, with a 10.53% ROE. Fortis Healthcare’s 53.42x P/E is below the 62.56x Industry P/E and the 54.86x peer average, but its 10.53% ROE is lower than both Apollo Hospitals and Max Healthcare.

Metric Fortis Healthcare
CMP (NSE) Rs 752.75
52-Week High / Low Rs 1,104.30 / Rs 745.35
Market Cap Rs 57,188 Cr
P/E (TTM) vs Industry P/E 53.42x vs 62.56x
P/B 5.78
ROE 10.53%
EPS (TTM) Rs 14.18
Dividend Yield 0.13%
Debt to Equity 0.35

Compare Fortis Healthcare Against Other Healthcare Sector Stocks

How Fortis Healthcare Compares Against Its Healthcare Sector Peers

The table below sets Fortis Healthcare against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company Market Cap (Rs Cr) P/E ROE Debt to Equity
Fortis Healthcare 57,188 53.42 10.53% 0.35
Apollo Hospitals Enterprise 1,12,225 51.67 20.48% 0.90
Max Healthcare Institute 84,581 58.05 13.42% 0.32
Peer average (2 companies) – 54.86 16.95% 0.61

Against this peer set, Fortis Healthcare’s 10.53% ROE is below the 16.95% peer average, and its P/E of 53.42x runs below the peer average of 54.86x. Fortis Healthcare’s 53.42x P/E is below the 62.56x Industry P/E and the 54.86x peer average, but its 10.53% ROE is lower than both Apollo Hospitals and Max Healthcare.

What Makes Fortis Healthcare Worth Watching in Healthcare

  • Valuation: A 53.42x P/E sits below the 62.56x Industry P/E.
  • Lower returns: A 10.53% ROE trails Apollo Hospitals at 20.48% and Max Healthcare at 13.42%.
  • Leverage: A debt to equity ratio of 0.35 is lower than Apollo Hospitals at 0.90 but higher than Max Healthcare at 0.32.

Fortis Healthcare Valuation: Is It Justified?

Fortis Healthcare’s 53.42x P/E is below the 62.56x Industry P/E and the 54.86x peer average, but its 10.53% ROE is lower than both Apollo Hospitals and Max Healthcare. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Sun Pharma the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Fortis Healthcare and other Healthcare sector stocks.

How to Track Fortis Healthcare Before You Invest

Before deciding whether Fortis Healthcare deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

  1. Open the Univest Screener and search for Fortis Healthcare to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
  2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
  3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
  4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Fortis Healthcare earns a place in the best stock in its sector conversation on the strength of a 10.53% ROE and a P/E of 53.42x against a 62.56x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Fortis Healthcare the best stock in its sector?

Ans. Fortis Healthcare has a 10.53% ROE and trades at 53.42x P/E against a 62.56x Industry P/E, and compares below the peer average ROE of 16.95% in this article’s named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Fortis Healthcare?

Ans. Fortis Healthcare was trading at Rs 752.75 on the NSE as of 13 October 2026, within its 52-week range of Rs 745.35 to Rs 1,104.30.

What sector does Fortis Healthcare belong to?

Ans. Fortis Healthcare is classified under the Healthcare sector on Univest.

How does Fortis Healthcare compare to its sector peers on P/E?

Ans. Fortis Healthcare’s P/E of 53.42x is below the 54.86x average of the 2 named peers compared in this article.

What is Fortis Healthcare’s return on equity?

Ans. Fortis Healthcare reported a return on equity of 10.53%, which is below the 16.95% average of its named peers in this comparison.

Should I invest in Fortis Healthcare based on its sector position?

Ans. Fortis Healthcare’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “Is Fortis Healthcare the best stock in its sector?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Fortis Healthcare has a 10.53% ROE and trades at 53.42x P/E against a 62.56x Industry P/E, and compares below the peer average ROE of 16.95% in this article’s named comparison, so the answer depends on what an investor is prioritising.”}}, {“@type”: “Question”, “name”: “What is the current share price of Fortis Healthcare?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Fortis Healthcare was trading at Rs 752.75 on the NSE as of 13 October 2026, within its 52-week range of Rs 745.35 to Rs 1,104.30.”}}, {“@type”: “Question”, “name”: “What sector does Fortis Healthcare belong to?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Fortis Healthcare is classified under the Healthcare sector on Univest.”}}, {“@type”: “Question”, “name”: “How does Fortis Healthcare compare to its sector peers on P/E?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Fortis Healthcare’s P/E of 53.42x is below the 54.86x average of the 2 named peers compared in this article.”}}, {“@type”: “Question”, “name”: “What is Fortis Healthcare’s return on equity?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Fortis Healthcare reported a return on equity of 10.53%, which is below the 16.95% average of its named peers in this comparison.”}}, {“@type”: “Question”, “name”: “Should I invest in Fortis Healthcare based on its sector position?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Fortis Healthcare’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.”}}]}



sector stocks Stock Market
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply